Dr. Jonathan Abele, MD
Claim this profileUniversity of Alberta
Studies Neuroendocrine Tumors
Studies Prostate Cancer
5 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Jonathan Abele, MD is currently running
PSMA PET/CT Scan
for Prostate Cancer
A two-centre prospective cohort phase III study of 18F-PSMA-1007 PET/CT imaging in specific patient populations: 1. Adults patients (≥18 years old) with a history of radical prostatectomy for treatment of prostate cancer, and a serum prostate specific antigen (PSA) ≥ 0.2 mcg/L 2. Adult patients with a history of radiotherapy, cryotherapy, or brachytherapy for treatment of prostate cancer, and a serum PSA progressively rising to ≥ 2 mcg/L (minimum two samples) OR a serum PSA doubling time of \< 9 months 3. Adult patients with a history of biopsy-proven prostate cancer and high-risk features for metastatic disease prior to treatment with radical prostatectomy, radiotherapy, cryotherapy, or brachytherapy. High-risk features include a Gleason score ≥ 7, serum PSA ≥ 20 mcg/L, OR minimum clinical T-stage T2c 4. Adult patients who do not meet criteria 1-3 but in whom a 18F-PDAM-1007 PET/CT scan is expected to provide clinical benefit as determined by a Urologist, Radiation Oncologist, Medical Oncologist, or Nuclear Medicine physician (licensed in Alberta) The safety of the investigational 18F-PSMA-1007 tracer will be evaluated in 3 ways: 1. The participant will be screened for adverse effects immediately post-injection 2. The participant will be screened for adverse effects immediately after the scan (approximately 2.5 hours after tracer injection) 3. The participant will be provided an information sheet and contact information for self-reporting of any delayed adverse events (1-7 days post injection) The incidence of and activity of non-specific bone lesions will be quantified and evaluated as follows: 1. All lesions categorized as non-specific bone lesions (PSMA-1007 SUVmax \> 2.5 but no corresponding lesion on CT) will be recorded 2. The SUVmax and anatomic location will be recorded for each lesion (max 5 per participant) 3. Recorded lesions will be evaluated a minimum of 1 year post-scan to determine whether they are benign or malignant based on previously published reference standard criteria (Arnfield et al., 2021) 4. Equivocal lesions will be considered unevaluable and will be excluded from assessment of accuracy
Recruiting2 awards Phase 3
18F-DOPA PET/CT Imaging Optimization
for undefined
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.
Recruiting2 awards Phase 35 criteria
More about Jonathan Abele, MD
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jonathan Abele, MD has experience with
- 18F-DOPA
- 18F-PSMA-1007
- Furosemide Injection
- 68Ga-HA-DOTATATE
Breakdown of trials Jonathan Abele, MD has run
Neuroendocrine Tumors
Neuroblastoma
Parkinson's Disease
Lewy Body Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan Abele, MD specialize in?
Jonathan Abele, MD focuses on Neuroendocrine Tumors and Prostate Cancer. In particular, much of their work with Neuroendocrine Tumors has involved treating patients, or patients who are undergoing treatment.
Is Jonathan Abele, MD currently recruiting for clinical trials?
Yes, Jonathan Abele, MD is currently recruiting for 3 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Jonathan Abele, MD has studied deeply?
Yes, Jonathan Abele, MD has studied treatments such as 18F-DOPA, 18F-PSMA-1007, Furosemide Injection.
What is the best way to schedule an appointment with Jonathan Abele, MD?
Apply for one of the trials that Jonathan Abele, MD is conducting.
What is the office address of Jonathan Abele, MD?
The office of Jonathan Abele, MD is located at: University of Alberta, Edmonton, Alberta T6G 2R3 Canada. This is the address for their practice at the University of Alberta.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.